Please select the option that best describes you:
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Extrapolating from the ADRIATIC trial.
Answer from: Medical Oncologist at Academic Institution
Obviously, there are no direct data, and the standard is EP chemotherapy. The cure rate in this situation is still suboptimal, but the majority of patients are cured. Adding IO might improve survival, but will most certainly increase cost and toxicity. I would discuss with patients, and I often tell...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Yes I would, and this is an appropriate question because only about 13% of patients in ADRIATIC were stage I/II, raising concerns about their representation. The forest plot, unlike in stage III, showed a confidence interval crossing 1, suggesting less clear benefit. However, SCLC is a systemic dise...
Comments
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
The randomized I-SABR results continue to intrigue...
The randomized I-SABR results continue to intrigue...
Answer from: Medical Oncologist at Community Practice
Great question and a common scenario! A clinical trial would be most appropriate, but I agree with Dr. @Bunn that the data is just not there. Extrapolating from ADRIATIC and from NSCLC studies, the case for adjuvant immunotherapy after chemo is strong. I would consider the two options presented...